Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses

International Journal of Cancer

Volumn 134, Issue 1, 2014, Pages 235-243

  Weiland, Timo ^a   Lampe, Johanna ^a   Essmann, Frank ^a   Venturelli, Sascha ^a   Berger, Alexander ^a   Bossow, Sascha ^b   Berchtold, Susanne ^a   Schulze Osthoff, Klaus ^a   Lauer, Ulrich M ^a   Bitzer, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

breast cancer; hepatoma; pancreatic cancer; therapy induced senescence; virotherapy

Indexed keywords

DOXORUBICIN; GEMCITABINE; MEASLES VACCINE; ONCOLYTIC MEASLES VACCINE VIRUS; ONCOLYTIC VIRUS; PACLITAXEL; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER THERAPY; CELL CYCLE ARREST; CELL KILLING; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; ONCOLYTIC VIROTHERAPY; PANCREAS CARCINOMA; PRIORITY JOURNAL; SENESCENCE; TUMOR CELL; VIROTHERAPY; VIRUS PARTICLE; VIRUS REPLICATION;

BREAST CANCER; HEPATOMA; PANCREATIC CANCER; THERAPY-INDUCED SENESCENCE; VIROTHERAPY;

ANTINEOPLASTIC AGENTS; CELL AGING; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MEASLES VACCINE; MEASLES VIRUS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84885948176     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28350     Document Type: Article

References (35)

1. Ewald JA, Desotelle JA, Wilding G, et al. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010; 102: 1536-46.
2. Rodier F, Campisi J,. Four faces of cellular senescence. J Cell Biol 2010; 192: 547-56.
3. Collado M, Serrano M,. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010; 10: 51-7.
4. Mooi WJ, Peeper DS,. Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med 2006; 355: 1037-46.
5. Crescenzi E, Palumbo G, Brady HJ,. Bcl-2 activates a programme of premature senescence in human carcinoma cells. Biochem J 2003; 375: 263-74.
6. Rebbaa A, Zheng X, Chou PM, et al. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 2003; 22: 2805-11.
7. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-46.
8. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 2006; 92: 9363-7.
9. Zhang R, Adams PD,. Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle 2007; 6: 784-9.
10. Zhang R, Chen W, Adams PD,. Molecular dissection of formation of senescence-associated hetero-chromatin foci. Mol Cell Biol 2007; 27: 2343-58.
11. Lawless C, Wang C, Jurk D, et al. Quantitative assessment of markers for cell senescence. Exp Gerontol 2010; 45: 772-8.
12. Kuilman T, Peeper DS,. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009; 9: 81-94.
13. Kahlem P, Dörken B, Schmitt CA,. Cellular senescence in cancer treatment: friend or foe? J Clin Invest 2004; 113: 169-74.
14. Jänicke RU, Sohn D, Essmann F, et al. The multiple battles fought by anti-apoptotic p21. Cell Cycle 2007; 6: 407-13.
15. Bourke MG, Salwa S, Harrington KJ, et al. The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 2011; 37: 618-32.
16. Eager RM, Nemunaitis J,. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 2011; 18: 305-17.
17. Cattaneo R, Miest T, Shashkova EV, et al. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-40.
18. Mahoney DJ, Stojdl DF,. Potentiating oncolytic viruses by targeted drug intervention. Curr Opin Mol Ther 2010; 12: 394-02.
19. Reddel RR,. Senescence: an antiviral defense that is tumor suppressive? Carcinogenesis 2010; 31: 19-26.
20. Horner SM, DeFilippis RA, Manuelidis L, et al. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol 2004; 78: 4063-73.
21. Kinjo T, Ham-Terhune J, Peloponese JM Jr, et al. Induction of reactive oxygen species by human T-cell leukemia virus type 1 tax correlates with DNA damage and expression of cellular senescence marker. J Virol 2010; 84: 5431-7.
22. Xin B, He Z, Yang X, et al. TRADD domain of Epstein-Barr virus transforming protein LMP1 is essential for inducing immortalization and suppressing senescence of primary rodent fibroblasts. J Virol 2001; 75: 3010-5.
23. Galanis E, Hartmann LC, Cliby WA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70: 875-82.
24. Galanis E,. Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther 2010; 88: 620-5.
25. Blechacz B, Splinter PL, Greiner S, et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006; 44: 1465-77.
26. Anderson BD, Nakamura D, Russell JS, et al. High CD46 Receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004; 64: 4919-26.
27. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
28. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-60.
29. Shay JW, Roninson IB,. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004; 23: 2919-33.
30. Yan Q, Wajapeyee N,. Exploiting cellular senescence to treat cancer and circumvent drug resistance. Cancer Biol Ther 2010; 9: 166-75.
31. Haugstetter AM, Loddenkemper C, Lenze D, et al. Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer 2010; 103: 505-9
32. Roberson RS, Kussick SJ, Vallieres E, et al. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005; 65: 2795-803
33. Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011; 479: 547-51
34. Diallo JS, Le Boeuf F, Lai F, et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther 2010; 18: 1123-9.
35. Ewald JA, Peters N, Desotelle JA, et al. A high-throughput method to identify novel senescence-inducing compounds. J Biomol Screen 2009; 14: 853-8.